(Information sent by the signing company)
Clairvoyant Therapeutics (“Clairvoyant”), a clinical-stage biotechnology company focused on the development of psychedelic drug therapies for the treatment of addiction, is pleased to announce that the dose has been administered to the first patient in the clinical-stage clinical trial. 2 from the company investigating psilocybin for the treatment of alcohol use disorder (AUD)
Clairvoyant’s randomized, controlled clinical trial, CLA-PSY-201, will evaluate the safety and efficacy of a 25-mg synthetic psilocybin capsule versus placebo for motivation-enhancing therapy (MET). Psilocybin is the pharmaceutical agent in certain mushrooms that is known to induce a temporary psychedelic state. “Dosing our first patient is a key milestone that we have been working towards for over two years,” said Damian Kettlewell, Clairvoyant’s CEO, adding, “We look forward to initiating further trials at leading universities and private clinical centers across Canada and Europe. With each step, we come closer to fulfilling our mission to develop a psilocybin therapy for ADHD patients.” “We are delighted to be part of the ongoing investigation of psilocybin as a therapeutic agent,” said Eugene Okorie, MD, FRCPC, clinical trial investigator at Okanagan Clinical Trials, where the first CLA patient is being treated. -PSY-201. “We hope to help advance the medical community’s understanding and thinking about the potential benefit of psilocybin for patients.”Clairvoyant aims to be the first company in the world to gain marketing authorization for psilocybin in Europe, the UK and Canada to benefit patients living with the disorder autism. In addition to treating the first patient in Canada, Clairvoyant has also received regulatory approval and has started the first two clinical centers in Finland. The company plans to register psilocybin therapy for ADHD in 2026 on two continents. Dustin Robinson, CEO of Iter Investments, which led Clairvoyant’s seed round along with investors Negev Capital and Ambria Capital, among others, commented the strengths of the firm’s approach: “As an early-stage investor, every deal we invest in carries a certain execution risk. Their first patient’s dosing of Clairvoyant is another example of how Clairvoyant mitigates this execution risk through of their detailed strategic plan, focused business strategy, and stellar teamwork. We look forward to continuing to work closely with Clairvoyant as we continue to execute on their plan.”About CLA-PSY-201 CLA-PSY-201 is a clinical trial comparing oral capsules of 25mg synthetic psilocybin with a placebo in the context of Motivational Enhancement Therapy (MET). The clinical trial is starting at approximately 15 clinical centers in Canada and Europe. Clairvoyant’s extensive therapist training program is being developed at each clinical center to ensure the highest professional and ethical standards. Provisional data reading is anticipated in mid-2023.About alcohol use disorder According to the World Health Organization, 283 million people over the age of 15 are at risk of an alcohol use disorder.i At the Globally, mortality from alcohol use is higher than that from diseases such as tuberculosis, HIV/AIDS, and diabetes.iAbout Clairvoyant Clairvoyant Therapeutics is a Canadian biotechnology company founded by an exceptional team with a proven clinical track record and extensive experience in developing drugs to bring them to market. Clairvoyant is conducting a Phase 2 randomized control trial of psilocybin therapy for alcohol use disorder (AUD) in multiple countries. Clairvoyant is committed to meeting the highest standards of verified environmental and social performance, the public transparency and legal accountability to balance benefit and purpose and is a B Corporation pending certification. Clairvoyant is a member of Life Science BC and the Biotechnology Innovation Organization (BIO). Learn more at www.clairvoyantrx.com and follow the company on LinkedIn and Twitter. i World Health Organization. Global Action Plan on Alcohol 2022-2030 to Strengthen Implementation of the Global Strategy to Reduce the Harmful Use of Alcohol First Draft. June 2021.
ContactContact name: Marlo TaylorContact description: Marlo Taylor
